Barrett’s Esophagus Test Identifies High-Risk Patients Missed by Standard Pathology
A study of 85 patients shows the TissueCypher test detected 15% with elevated cancer progression risk despite a non-dysplastic diagnosis.
Category: Uncategorized
Uncategorized
Latest
Uncategorized
Latest
Color Health Partners with CDC to Increase Access to COVID Testing
Color Health is providing free COVID testing through the CDC's Increasing Community Access to Testing program.
Uncategorized
Latest
Ortho Clinical Diagnostics, Thermo Fisher Scientific Partner on QC Solutions
Ortho Clinical Diagnostics has a distribution agreement with Thermo Fisher Scientific to provide and support MAS Quality Controls and LabLink xL Quality Assurance Software through Ortho's Vitros QC Solutions to Vitros System customers worldwide.
Clinical Chemistry
Latest
Routine Lab Tests May Help Identify Physical Effects of PTSD
Researchers at Mass General Brigham identified 16 routine lab markers, including cholesterol and glucose, linked to PTSD’s physical effects, suggesting standard tests could aid in assessing the disorder’s multi-organ impact.
Flow Cytometry
Latest
Bio-Rad Expands Antibody Labeling Kits for Flow Cytometry and Western Blot
Bio-Rad has expanded its TrailBlazer StarBright Dye Label Kits to 32 options, now available in Europe for flow cytometry and fluorescent western blot applications, according to the company.
Mass Spectrometry
Latest
New Data Supports Multi-Omic Blood Test for Early Ovarian Cancer Detection
AOA Dx presented data at AACR 2026 supporting its AKRIVIS GD Test System, a multi-omic, blood-based assay for early ovarian cancer detection in symptomatic women, reporting an AUC of 0.92 in clinical controls.
Immunoassay
Latest
Roche Receives CE Mark for Alzheimer’s Disease Blood Test
Roche has received CE mark approval for its Elecsys pTau217 blood test, designed to aid in Alzheimer’s disease diagnosis by detecting amyloid pathology in patients with cognitive decline.
Molecular Diagnostics
Latest
Medicare Expands Coverage for Cancer Immunotherapy Monitoring Test
CMS has expanded Medicare coverage for Personalis’ NeXT Personal MRD test, now allowing immunotherapy monitoring in late-stage solid tumor patients, supported by recent clinical evidence from Vall d’Hebron Institute of Oncology.
Point-of-Care
Latest
Roche Receives FDA Clearance for Point-of-Care Bordetella Test
The cobas liat system delivers PCR results in 15 minutes, detecting and differentiating between three Bordetella pathogens including whooping cough.